Mbx Biosciences Inc (MBX)

$36.31 -0.16 (-0.44%)
Market Cap 1.64B
Revenue (ttm) 0.00
Net Income (ttm) -61.92M
EPS (ttm) N/A
PE Ratio 0.00
Forward PE N/A
Profit Margin 0.00%
Debt to Equity Ratio 0.00
Volume 816,100
Avg Vol 778,396
Day's Range N/A - N/A
Shares Out 44.90M
Stochastic %K 97%
Beta 0.86
Analysts Strong Sell
Price Target $59.33

Company Profile

MBX Biosciences, Inc., a clinical-stage biopharmaceutical company, focuses on the discovery and development of precision peptide therapies for the treatment of endocrine and metabolic disorders. Its lead product candidate is MBX 2109, a parathyroid hormone peptide prodrug, which is in Phase 2 clinical trial for the treatment of chronic hypoparathyroidism. The company is also developing MBX 1416, a long-acting glucagon-like peptide-1 (GLP-1) receptor antagonist that is in Phase 1 clinical trial a...

Industry: Biotechnology
Sector: Healthcare
Phone: 317 659 0200
Website: mbxbio.com
Address:
11711 North Meridian Street, Suite 300, Carmel, United States
SocioCobb
SocioCobb Jan. 13 at 10:42 PM
$MBX Yeah, I tap into the quantum field for my tickers. Use the force, baby!
0 · Reply
loopsterthe1
loopsterthe1 Jan. 11 at 5:08 PM
$MBX Need news
0 · Reply
loopsterthe1
loopsterthe1 Jan. 11 at 5:07 PM
$MBX
0 · Reply
loopsterthe1
loopsterthe1 Jan. 11 at 5:06 PM
$MBX nice close now tomorrow more green coming!!
0 · Reply
MakeM0ney_444
MakeM0ney_444 Jan. 8 at 7:45 PM
$MBX today looks like a nice day to add a bit even though my cb is $25 rn
0 · Reply
russwise
russwise Jan. 7 at 3:15 PM
$MBX UBS initiated coverage today with a $60 PT.
0 · Reply
OfficialStocktwitsUser
OfficialStocktwitsUser Jan. 1 at 3:28 AM
$MBX RSI: 58.52, MACD: 1.1634 Vol: 1.98, MA20: 30.50, MA50: 26.79 ⚪ HOLD - Sideways 👉 https://quantumstockalerts.com Disclaimer: I am not a financial advisor. This post reflects personal analysis and opinions only. Please do your own research before investing or trading.
0 · Reply
ApexValueTrader
ApexValueTrader Dec. 27 at 6:15 AM
$MBX Risk tolerance remains selective and tied closely to execution credibility. Governance alignment can reduce perceived uncertainty. Durability across environments would extend investor horizons. As performance stabilizes, the path forward can strengthen.
1 · Reply
SocioCobb
SocioCobb Dec. 24 at 4:50 PM
$MBX Another 2x banger since form 4!
0 · Reply
NeptuneNetWorth
NeptuneNetWorth Dec. 24 at 10:24 AM
$MBX Future price discovery depends on how management navigates capital constraints while advancing core initiatives. Long-term optimism depends on disciplined follow-through.
0 · Reply
Latest News on MBX
MBX Biosciences to Provide 2026 Outlook and Business Update at 44th Annual J.P. Morgan Healthcare Conference

Jan 11, 2026, 4:00 PM EST - 2 days ago

MBX Biosciences to Provide 2026 Outlook and Business Update at 44th Annual J.P. Morgan Healthcare Conference

Microbix Biosystems Inc. (MBX:CA) Q4 2025 Earnings Call Transcript

Dec 18, 2025, 1:47 PM EST - 26 days ago

Microbix Biosystems Inc. (MBX:CA) Q4 2025 Earnings Call Transcript

MBX Biosciences to Present at the 44th Annual J.P. Morgan Healthcare Conference on January 13

Dec 15, 2025, 8:00 AM EST - 4 weeks ago

MBX Biosciences to Present at the 44th Annual J.P. Morgan Healthcare Conference on January 13

MBX Biosciences to Participate in the 37th Annual Piper Sandler Healthcare Conference

Nov 18, 2025, 8:00 AM EST - 2 months ago

MBX Biosciences to Participate in the 37th Annual Piper Sandler Healthcare Conference

MBX Biosciences Reports Third Quarter 2025 Financial Results and Recent Corporate Highlights

Nov 6, 2025, 8:00 AM EST - 2 months ago

MBX Biosciences Reports Third Quarter 2025 Financial Results and Recent Corporate Highlights

Biotech is back. Here's why these rallying stocks belong in your portfolio now.

Nov 3, 2025, 9:58 AM EST - 2 months ago

Biotech is back. Here's why these rallying stocks belong in your portfolio now.

ABBV ALNY AMGN BMY LLY MDGL MEDI

MBX Biosciences to Participate in November Investor Conferences

Oct 20, 2025, 8:00 AM EDT - 3 months ago

MBX Biosciences to Participate in November Investor Conferences

MBX Biosciences to Participate in the Stifel 2025 Virtual Cardiometabolic Forum

Sep 29, 2025, 8:00 AM EDT - 3 months ago

MBX Biosciences to Participate in the Stifel 2025 Virtual Cardiometabolic Forum

Stitch Fix Posts Q4 Results, Joins Transocean, MBX Biosciences And Other Big Stocks Moving Lower In Thursday's Pre-Market Session

Sep 25, 2025, 8:24 AM EDT - 3 months ago

Stitch Fix Posts Q4 Results, Joins Transocean, MBX Biosciences And Other Big Stocks Moving Lower In Thursday's Pre-Market Session

RIG SFIX

MBX Biosciences, Inc. - Special Call

Sep 24, 2025, 9:27 PM EDT - 3 months ago

MBX Biosciences, Inc. - Special Call

MBX Biosciences Announces Pricing of Upsized Public Offering

Sep 24, 2025, 9:15 PM EDT - 3 months ago

MBX Biosciences Announces Pricing of Upsized Public Offering

MBX Biosciences Looks A Buy As Hypoparathyroidism Data Wows Market

Sep 22, 2025, 5:10 PM EDT - 4 months ago

MBX Biosciences Looks A Buy As Hypoparathyroidism Data Wows Market

MBX Biosciences Announces Proposed Public Offering

Sep 22, 2025, 4:14 PM EDT - 4 months ago

MBX Biosciences Announces Proposed Public Offering

MBX Biosciences Announces Once-Weekly Canvuparatide Achieved Primary Endpoint in Phase 2 Trial with 63% Responder Rate at 12 Weeks; 79% Responder Rate at 6 Months in Open-Label Extension

Sep 22, 2025, 7:00 AM EDT - 4 months ago

MBX Biosciences Announces Once-Weekly Canvuparatide Achieved Primary Endpoint in Phase 2 Trial with 63% Responder Rate at 12 Weeks; 79% Responder Rate at 6 Months in Open-Label Extension

MBX Biosciences to Provide Topline Results from its Phase 2 Trial of Potential Once-Weekly Canvuparatide for Hypoparathyroidism (HP) on Monday, September 22

Sep 19, 2025, 4:18 PM EDT - 4 months ago

MBX Biosciences to Provide Topline Results from its Phase 2 Trial of Potential Once-Weekly Canvuparatide for Hypoparathyroidism (HP) on Monday, September 22

MBX Biosciences Doses First Participant in Phase 1 Trial of MBX 4291 for the Treatment of Obesity

Sep 4, 2025, 8:00 AM EDT - 4 months ago

MBX Biosciences Doses First Participant in Phase 1 Trial of MBX 4291 for the Treatment of Obesity

Microbix Biosystems Inc. (MBXBF) Q2 2025 Earnings Call Transcript

Aug 14, 2025, 2:00 PM EDT - 5 months ago

Microbix Biosystems Inc. (MBXBF) Q2 2025 Earnings Call Transcript

MBX Biosciences Reports Second Quarter 2025 Financial Results and Recent Corporate Highlights

Aug 7, 2025, 8:00 AM EDT - 5 months ago

MBX Biosciences Reports Second Quarter 2025 Financial Results and Recent Corporate Highlights

MBX Biosciences Appoints Andreas Moraitis, M.D., as Senior Vice President of Clinical Development

Jun 23, 2025, 8:00 AM EDT - 7 months ago

MBX Biosciences Appoints Andreas Moraitis, M.D., as Senior Vice President of Clinical Development

MBX Biosciences Announces IND Submission of MBX 4291, its Long-acting GLP1/GIP Receptor Co-agonist Prodrug for the Treatment of Obesity

Jun 16, 2025, 8:00 AM EDT - 7 months ago

MBX Biosciences Announces IND Submission of MBX 4291, its Long-acting GLP1/GIP Receptor Co-agonist Prodrug for the Treatment of Obesity

MBX Biosciences to Present at the American Diabetes Association 85th Scientific Sessions

Jun 10, 2025, 8:00 AM EDT - 7 months ago

MBX Biosciences to Present at the American Diabetes Association 85th Scientific Sessions

MBX Biosciences: Consider Peptide Developer With GLP Drugs As A Speculative Buy

May 31, 2025, 7:24 AM EDT - 8 months ago

MBX Biosciences: Consider Peptide Developer With GLP Drugs As A Speculative Buy

MBX Biosciences to Participate in June Investor Conferences

May 20, 2025, 8:00 AM EDT - 8 months ago

MBX Biosciences to Participate in June Investor Conferences

MBX Biosciences Reports First Quarter 2025 Financial Results and Recent Corporate Highlights

May 12, 2025, 8:00 AM EDT - 8 months ago

MBX Biosciences Reports First Quarter 2025 Financial Results and Recent Corporate Highlights

MBX Biosciences to Participate in Citizens and RBC May Investor Conferences

Apr 22, 2025, 8:00 AM EDT - 9 months ago

MBX Biosciences to Participate in Citizens and RBC May Investor Conferences

MBX Biosciences to Participate in the 24th Annual Needham Virtual Healthcare Conference

Mar 26, 2025, 8:00 AM EDT - 10 months ago

MBX Biosciences to Participate in the 24th Annual Needham Virtual Healthcare Conference

MBX Biosciences Reports Fourth Quarter and Full Year 2024 Financial Results and Recent Corporate Highlights

Mar 17, 2025, 8:00 AM EDT - 10 months ago

MBX Biosciences Reports Fourth Quarter and Full Year 2024 Financial Results and Recent Corporate Highlights

MBX Biosciences Announces Additions to Leadership Team

Mar 5, 2025, 8:00 AM EST - 11 months ago

MBX Biosciences Announces Additions to Leadership Team

MBX Biosciences Completes Enrollment in Phase 2 Avail™ Trial of MBX 2109 (Canvuparatide) for Hypoparathyroidism

Mar 3, 2025, 8:00 AM EST - 11 months ago

MBX Biosciences Completes Enrollment in Phase 2 Avail™ Trial of MBX 2109 (Canvuparatide) for Hypoparathyroidism

MBX Biosciences to Participate in March Investor Conferences

Feb 18, 2025, 8:00 AM EST - 11 months ago

MBX Biosciences to Participate in March Investor Conferences

MBX Biosciences Announces Positive Phase 1 Topline Results for MBX 1416 for the Treatment of Post-bariatric Hypoglycemia

Jan 7, 2025, 7:00 AM EST - 1 year ago

MBX Biosciences Announces Positive Phase 1 Topline Results for MBX 1416 for the Treatment of Post-bariatric Hypoglycemia

MBX Biosciences Announces Last Subject Last Visit in Phase 1 Trial of MBX 1416 for the Treatment of Post-Bariatric Hypoglycemia

Nov 18, 2024, 8:00 AM EST - 1 year ago

MBX Biosciences Announces Last Subject Last Visit in Phase 1 Trial of MBX 1416 for the Treatment of Post-Bariatric Hypoglycemia

MBX Biosciences to Participate in Upcoming November Investor Conferences

Oct 28, 2024, 8:00 AM EDT - 1 year ago

MBX Biosciences to Participate in Upcoming November Investor Conferences

MBX Biosciences Presents MBX 2109 Phase 2 Avail™ Hypoparathyroidism Trial Rationale and Design at the ASBMR 2024 Annual Meeting

Sep 30, 2024, 8:00 AM EDT - 1 year ago

MBX Biosciences Presents MBX 2109 Phase 2 Avail™ Hypoparathyroidism Trial Rationale and Design at the ASBMR 2024 Annual Meeting

MBX Biosciences Announces Closing of Upsized Initial Public Offering, Including Full Exercise of Underwriters' Option to Purchase Additional Shares

Sep 16, 2024, 4:05 PM EDT - 1 year ago

MBX Biosciences Announces Closing of Upsized Initial Public Offering, Including Full Exercise of Underwriters' Option to Purchase Additional Shares

U.S. IPO Weekly Recap: 3 Biotechs Lead Active September IPO Market

Sep 14, 2024, 5:00 AM EDT - 1 year ago

U.S. IPO Weekly Recap: 3 Biotechs Lead Active September IPO Market

BCAX GLXG TDTH XCH ZBIO

MBX Biosciences shares surge 44% in blockbuster Nasdaq debut

Sep 13, 2024, 12:36 PM EDT - 1 year ago

MBX Biosciences shares surge 44% in blockbuster Nasdaq debut

MBX Biosciences raises $163.2 mln in US IPO

Sep 12, 2024, 7:20 PM EDT - 1 year ago

MBX Biosciences raises $163.2 mln in US IPO

MBX Biosciences Announces Pricing of Initial Public Offering

Sep 12, 2024, 7:11 PM EDT - 1 year ago

MBX Biosciences Announces Pricing of Initial Public Offering

SocioCobb
SocioCobb Jan. 13 at 10:42 PM
$MBX Yeah, I tap into the quantum field for my tickers. Use the force, baby!
0 · Reply
loopsterthe1
loopsterthe1 Jan. 11 at 5:08 PM
$MBX Need news
0 · Reply
loopsterthe1
loopsterthe1 Jan. 11 at 5:07 PM
$MBX
0 · Reply
loopsterthe1
loopsterthe1 Jan. 11 at 5:06 PM
$MBX nice close now tomorrow more green coming!!
0 · Reply
MakeM0ney_444
MakeM0ney_444 Jan. 8 at 7:45 PM
$MBX today looks like a nice day to add a bit even though my cb is $25 rn
0 · Reply
russwise
russwise Jan. 7 at 3:15 PM
$MBX UBS initiated coverage today with a $60 PT.
0 · Reply
OfficialStocktwitsUser
OfficialStocktwitsUser Jan. 1 at 3:28 AM
$MBX RSI: 58.52, MACD: 1.1634 Vol: 1.98, MA20: 30.50, MA50: 26.79 ⚪ HOLD - Sideways 👉 https://quantumstockalerts.com Disclaimer: I am not a financial advisor. This post reflects personal analysis and opinions only. Please do your own research before investing or trading.
0 · Reply
ApexValueTrader
ApexValueTrader Dec. 27 at 6:15 AM
$MBX Risk tolerance remains selective and tied closely to execution credibility. Governance alignment can reduce perceived uncertainty. Durability across environments would extend investor horizons. As performance stabilizes, the path forward can strengthen.
1 · Reply
SocioCobb
SocioCobb Dec. 24 at 4:50 PM
$MBX Another 2x banger since form 4!
0 · Reply
NeptuneNetWorth
NeptuneNetWorth Dec. 24 at 10:24 AM
$MBX Future price discovery depends on how management navigates capital constraints while advancing core initiatives. Long-term optimism depends on disciplined follow-through.
0 · Reply
daintylava
daintylava Dec. 23 at 8:21 PM
$MBX Bullish, lots of hedge fund and insider buying. (Not financial advice)
0 · Reply
daintylava
daintylava Dec. 23 at 8:20 PM
$MBX Buy alert, catch this dip! You could sell when it goes back to 33-34. (Not financial advice)
0 · Reply
albertoaguinaga
albertoaguinaga Dec. 23 at 3:25 PM
$MBX
0 · Reply
OfficialStocktwitsUser
OfficialStocktwitsUser Dec. 23 at 6:27 AM
$MBX RSI: 54.08, MACD: 1.3611 Vol: 2.36, MA20: 30.93, MA50: 24.68 🔴 SELL - Downtrend 👉 https://quantumstockalerts.com Disclaimer: I am not a financial advisor. This post reflects personal analysis and opinions only. Please do your own research before investing or trading.
0 · Reply
JarvisFlow
JarvisFlow Dec. 19 at 2:44 PM
Stifel has adjusted their stance on MBX Biosciences ( $MBX ), setting the rating to Buy with a target price of 45 → 50.
0 · Reply
SocioCobb
SocioCobb Dec. 12 at 12:16 PM
$MBX
0 · Reply
russwise
russwise Dec. 4 at 9:08 PM
$MBX https://investors.mbxbio.com/stock-information/analyst-coverage So Goldman does not cover MBX until TODAY. And then issues an $18 target price. Whatever.
1 · Reply
DrWodo
DrWodo Dec. 4 at 3:29 PM
$MBX gobble gobble. Scooped at $28 at the open- thanks so much.
0 · Reply
www_larval_com
www_larval_com Dec. 4 at 2:42 PM
$BIOA 5%[17%] $KXIN 4%[-6%] $UPC 4%[15%] $SLMT -4%[-11%] $MBX 4%[-7%] most notable movement within the first minutes of trading.
1 · Reply
kulladpizza
kulladpizza Dec. 4 at 2:41 PM
$MBX Sold and moved on!
0 · Reply
erevnon
erevnon Dec. 4 at 2:37 PM
Goldman Sachs initiates coverage on MBX Biosciences $MBX at Sell rating and announces a price target of https://marketsblock.com/stock-upgrades-and-downgrades/
0 · Reply
DrWodo
DrWodo Dec. 4 at 2:19 PM
$MBX time to buy!
0 · Reply